Our results revealed that high expression level of SH2D3C is associated with the resistance of NSCLC cell lines to doxorubicin, mitoxantrone, GSK1070916, obatoclax mesylate, alisertib, NSC319726, mitomycin-C, bleomycin, etoposide, pelitinib, and BX-912 (Figure 6A). The gene discussed is SH2D3C; the disease is non-small cell lung carcinoma.